EMA Authorised: Mycamine (micafungin) — Sandoz Pharmaceuticals d.d.

View source ↗

Summary

The EMA authorised Mycamine (micafungin) for candidiasis, with Sandoz Pharmaceuticals d.d. as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidiasis

Drugs mentioned

• Mycamine (Micafungin)

Snippet

Status: Authorised. Therapeutic area: Candidiasis. MAH: Sandoz Pharmaceuticals d.d.. Decision date: 04/08/2025